Oncodesign's
corporate fact sheet
 Download
Latest News
Oncodesign and Ipsen in collaboration against the LRRK2
Parkinson's disease target
January 5,
2012
More
EORTC-NCI-AACR 2011 symposium, San Francisco
November 12-16,
2011
More
|
|
Pharmacological expertise
for anticancer therapies from target to patient : a unique oncology
preclinical CRO |
-
 More than 1000 studies conducted with new compounds
and reference drugs, 230 clients worldwide
- Proof of concept in human tumor xenograft models,
> 300 tumor cell lines available
- Emphasis on pharmacokinetic/pharmacodynamic
relationship
- Translational research using pharmaco-imaging (MRI,
PET) for biomarker validation
|
|
Home
